Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT03116698 | A Study to Evaluate Two Concentrations of DFD-07 Cream, in Subjects With Actinic Keratosis (AK) of the Face and/or Scalp Over a 12-week Treatment Period | PHASE2 | COMPLETED | 240 | — | — | Feb 14, 2017 | Jul 5, 2018 | Apr 24, 2019 | 20 | United States |
The proportion of subjects with complete clearance (absence of clinically visible or palpable AK lesions in the treatment area) of AK lesions at the End of Study Visit at 16 weeks (12 weeks treatment and 4 weeks treatment-free follow-up)
| Arm | Type | Description |
|---|---|---|
| Low dose DFD07 once daily | EXPERIMENTAL | - |
| High dose DFD07 once daily | EXPERIMENTAL | - |
| High dose DFD07 twice daily | EXPERIMENTAL | - |
| Placebo twice daily | PLACEBO_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| Low dose DFD07 once daily | DRUG | Low dose DFD07 once daily |
| High dose DFD07 once daily | DRUG | High dose DFD07 once daily |
| High dose DFD07 twice daily | DRUG | High dose DFD07 twice daily |
| Placebo twice daily | DRUG | Placebo twice daily |
Inclusion: 1. Subject understands the study procedures, is willing to comply with the study procedures and required visits, and agrees to participate by giving written informed consent. Subjects with a legal guardian, must have the written informed consent of the legal guardian. 2. Subject (or lega...